Perennial allergic rhinitis. Other allergic rhinitis
Conditions
Interventions
Subcutaneous immunotherapy with the Aero allergens.
Treatment - Drugs
Subcutaneous immunotherapy with the Aero allergens
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 51 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: The risk of perennial allergic rhinitis; Positive skin test to allergens in the air; Clinical signs associated with skin test Exclusion criteria: History of autoimmune disease; Patients with systemic corticosteroids or immunosuppressive drugs for reasons other than allergic disease on the immune system use to be effective; Pregnancy; Immunocompromised patients, patients who have uncontrolled allergic asthma; Patients with malnutrition; Patients who received beta-blocker drugs; Patients with a history of anaphylaxis; patients With coexisting cardiovascular disease; During treatment, patients who are experiencing systemic reactions; Patients with mental disorders
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the expression of IL- 4, FoxP3, TGF-ß, IL-17, IL-10 and IFN-? genes in peripheral blood of allergic rhinitis patients. Timepoint: Befor & 3 months after the trial. Method of measurement: Real Time-PCR Technique.;Quality of life. Timepoint: Befor and 3 months after Rush immunotherapy. Method of measurement: Questionnaires SNOT22 and Mini RQLQ. | — |
Secondary
| Measure | Time frame |
|---|---|
| Systemic reactions to immunotherapy. Timepoint: At every turn immunotherapy. Method of measurement: Clinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirabass Salmani
Mashahd University of Medical Sciences
Outcome results
None listed